Author(s)
Kristensen LE1, Coates LC2, Mease PJ3, Nash P4, Ogdie AR5, Tillett W6, Gisondi P7, Ink B8, Prickett AR8, Assudani D8, Bajracharya R8, Taieb V9, Willems D10, Lambert J9, Walsh JA11
1The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, 2Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, UK, 3Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, USA, 4School of Medicine, Griffith University, Brisbane, QLD, Australia, 5Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 6Royal National Hospital of Rheumatic Diseases, Bath, UK, 7Department of Medicine, Section of Dermatology and Venereology, Università degli Studi di Verona, Verona, Italy, 8UCB Pharma, Slough, UK, 9UCB Pharma, Colombes, France, 10UCB Pharma, Eupen, WLG, Belgium, 11Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, USA
OBJECTIVES: To examine the association between achieving stringent clinical disease control and quality of life (QoL) improvements in patients with psoriatic arthritis (PsA). METHODS: Post hoc analysis of Week 16 results from bimekizumab phase 3 studies, BE OPTIMAL (NCT03895203; biologic disease-modifying antirheumatic drug [bDMARD]-naïve patients) and BE COMPLETE (NCT03896581; inadequate response/intolerance to TNF inhibitors [TNFi-IR]).1,2 Patients achieving disease control criteria (American College of Rheumatology [ACR]: <20% improvement from baseline, ≥20% to <50%, ≥50% to <70%, ≥70%; minimal disease activity [MDA]; Psoriatic Arthritis Response Criteria [PsARC]) at Week 16 were pooled regardless of treatment arm, by study. The association between achieving these criteria and mean changes from baseline in QoL measures (EQ-5D-3L VAS, EQ-5D-3L utility [UK tariff] and SF-36 PCS) was assessed (observed case). RESULTS: 821/852 (96.4%) bDMARD-naïve, 388/400 (97.0%) TNFi-IR patients completed Week 16. Baseline mean (SD) EQ-5D-3L VAS, EQ-5D-3L utility and SF-36 PCS (bDMARD‑naïve/TNFi-IR) scores: 56.3 (20.0)/54.4 (20.4), 0.63 (0.23)/0.56 (0.27) and 37.6 (9.4)/36.3 (9.4). Patients achieving greater ACR responses demonstrated greater mean (95% CI) improvements in EQ-5D-3L VAS (bDMARD-naïve: <20%: −1.2 [−3.3, 0.9], ≥20%<50%: 11.0 [7.7, 14.3], ≥50%<70%: 14.0 [10.1, 17.9], ≥70%: 23.7 [19.7, 27.7]; TNFi-IR: 0.5 [−2.7, 3.8], 9.3 [4.9, 13.8], 11.7 [5.3, 18.1], 29.5 [23.0, 35.9]). MDA responders showed greater mean (95% CI) improvements in EQ-5D-3L VAS versus non-responders (bDMARD-naïve: non-responders 2.9 [1.1, 4.8] versus responders 17.5 [14.7, 20.3]; TNFi-IR: 3.5 [0.8, 6.1] versus 20.9 [16.0, 25.8]). Greater mean (95% CI) EQ-5D-3L VAS improvements were also demonstrated in PsARC responders versus non‑responders (bDMARD-naïve: −1.6 [−4.3, 1.0] versus 12.3 [10.3, 14.2]; TNFi-IR: −2.1 [−6.3, 2.2] versus 14.1 [11.2, 17.1]). The trends were similar for EQ-5D-3L utility and SF-36 PCS. CONCLUSIONS: Patients with PsA achieving stringent disease control demonstrated greater improvements in QoL at Week 16. REFERENCES: 1. McInnes IB. Ann Rheum Dis 2022;81:206–7; 2. Merola JF. Ann Rheum Dis 2022;81:167–8.
Conference/Value in Health Info
2022-11, ISPOR Europe 2022, Vienna, Austria
Value in Health, Volume 25, Issue 12S (December 2022)
Code
PCR117
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
SDC: Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)